## THE LANCET Infectious Diseases

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet Infect Dis* 2020; published online March 24. https://doi.org/10.1016/S1473-3099(20)30176-6.

## Supplementary Table 1 Maternal laboratory results of patients with COVID-19 pneumonia

C1	patients with COVID-19 pneumonia (n = 7)								
Characteristics	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7		
Imaging examin	ation (chest C	T)							
Typical signs	Yes	Yes	Yes	Yes	Yes	Yes	Yes		
of viral									
infection									
Bilateral	Yes	Yes	Yes	Yes	No	Yes	Yes		
pneumonia									
Unilateral	No	No	No	No	Yes	No	No		
pneumonia									
Blood routine									
Leucocytes (×	normal	normal	normal	normal	normal	normal	normal		
109 per L)									
Neutrophils%	increased	normal	increased	increased	normal	increased	increased		
	(80%)		(76.3%)	(81.2%)		(83.5%)	(87%)		
Lymphocytes	decreased,	normal	decreased,	decreased	normal	decreased	decreased,		
(×10 <sup>9</sup> per L)	(0.97)		(0.89)	(1.11)		(0.64)	(0.9)		
Platelets (×10 <sup>9</sup>	decreased		decreased	normal	normal	normal	normal		
per L)	(83)	normal	(116)						
НВ	normal	normal	normal	normal	normal	normal	normal		
Coagulation fun	ction								
APTT	normal	normal	normal	increased	normal	normal	increased		
				(43.7)			(45.7)		
Prothrombin	normal	normal	normal	normal	normal	normal	normal		
time (s)									
D-dimer	increased	increased	increased	increased	increased	increased	increased		
	(1.42)	(2.05)	$(1 \cdot 1)$	(0.95)	(0.95)	(2.11)	(1.17)		
Blood biochemi	stry								
AST (U/L)	normal	normal	normal	normal	normal	normal	increased		
							(153)		
ALT (U/L)	normal	increased	normal	normal	normal	normal	increased		
		(47)					(249)		
Albumin (g/L)	normal	decreased	decreased	decreased	decreased	normal	decreased		
		(32.8)	(30.2)	(33.2)	(34.2)		(31.7)		
Total bilirubin	normal	normal	normal	normal	normal	normal	normal		
(µmol/L)									
Blood urea	normal	decreased	decreased	normal	decreased	normal	decreased		
nitrogen		(2.3)	(2.17)		(1.8)		(1.5)		
(mmol/L)									
Serum	normal	normal	normal	normal	normal	normal	normal		
creatinine									
(µmol/L)									
Creatine	normal	increased	normal	normal	-	normal	-		

kinase (U/L)		(188)					
Lactate	increased	increased	increased	normal	increased	normal	increased
dehydrogenase	(323)	(247)	(213)		(260)		(354)
(U/L)							
Glucose	increased	normal	normal	normal	normal	normal	increased
(mmol/L)	(6.07)						(6.47)
Infection-related	l biomarkers						
Procalcitonin	increased	normal	increased	-	increased	normal	increased
(ng/mL)	(0.05)		(0.12)		(0.22)		(0.07)
C-reactive	increased	increased	increased	increased	increased	increased	increased
protein (mg/L)	(33-2)	(38.7)	(19.4)	(20.8)	(49.5)	(20.9)	(40)
Erythrocyte	increased	increased	normal	-	increased	-	increased
sedimentation	(26)	(34)			(81)		(30)
rate (mm/h)							
Serum ferritin	increased	normal	increased	normal	normal	normal	increased
(ng/mL)	(151.9)		(194.5)				(230-2)
Interleukin-6	increased	increased	-	-	-	increased	increased
(pg/mL)	(44-18)	(14.5)				(30-33)	(43.72)
Co-infection							
Other viruses	No	influenza	No	No	influenza	No	No
		A			A		
Bacteria	Legionella	No	No	No	No	No	No
	pneumophila						
Fungus	No	No	No	No	No	No	No

## Supplementary Table 2 Maternal treatment of patients with COVID-19 pneumonia

Characterist	patients with COVID-19 pneumonia (n = 7)							
ics	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	
Oxygen	Nasal	Nasal	Nasal	Nasal	Nasal	Nasal	Nasal	
therapy	catheter	catheter	catheter	catheter	catheter	catheter	catheter	
Antibiotic	moxiflox	Moxifloxac	Moxifloxaci	moxifloxaci	Cephalospo	moxifloxaci	Cephalosp	
treatment	acin	in;	n ;	n ;	rin;	n ;	orin	
		Azithromy	Cephalospor	Cephalospo	Ornidazole	Cephalospo		
		cin	in	rin		rin		
Antiviral	Ganciclo	Oseltamivi	Interferon,Ji	Interferon,Ji	Arbidol	Interferon	Arbidol	
treatment	vir,	r, abidol,	nyebaidu	nyebaidu				
	interfero	Jinyebaidu	granules	granules				
	n,	granules,						
	Lianhuaq	Lianhuaqin						
	ingwen	gwen						
Glucocortic	Yes	Yes	Yes	Yes	No	Yes	No	
oids								
Intravenous	No	No	No	No	No	No	No	
immunoglo								

bulin							
therapy							
Method of	Cesarean	Cesarean	Cesarean	Cesarean	Cesarean	Cesarean	Cesarean
delivery	section	section	section	section	section	section	section
							Mature;
	Mature;	Mature;	Mature;			Mature;	History of
Indication	COVID-	Precious	Fetal	Mature;	Mature;	History of	C-section;
for C-	19	fetus;	distress;	History of	Failure trial	•	COVID-
section	pneumon	Placentas	COVID-19	C-section	vaginal	C-section; Parturient	19
	ia	racquet	pneumonia				pneumoni
							a
Terminatio							
n of							
gestational	40	38+5	41+5	37	$40^{+6}$	38+2	$38^{+4}$
age							
(weeks)							
	combine	combined spinal-	general anesthesia	combined	combined	combined	combined
Anesthesia mode	d spinal-			spinal-	spinal-	spinal-	spinal-
mode	epidural	epidural	anesmesia	epidural	epidural	epidural	epidural
Intraoperati							
ve oxygen	98%	98%	98%	98%	99%	99%	99%
saturation							
Transfusion	1000	750	1500	1500	1000	500	1000
volume(ml)	1000				1000		1000
Amount of							
bleeding	200	300	100	50	300	200	200
(ml)							
Oxytocin	30	20	30	30	20	30	20
use (U)	30	20	30	30	20	30	20